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ABSTRACT OF THE DISSERTATION
Controlling the Oxygen Microenvironment: The Role of HIF-1α in Early Tumor Progression
by
Sandra Lam
Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, 2018
Professor Steven George, Chair
Professor Lori Setton, Co-Chair
Cancer drug efficacy has remained a critical obstacle for researchers as it has one of the lowest
probabilities of success compared to other diseases. One method to help improve this success
rate is to create better tumor models on which to perform the drug testing. With growing
interesting in microphysiological systems, scientists can create more advanced in vitro models of
human organ systems as well as diseased states. These “organ-on-a-chip” platforms aim to
improve drug response prediction for both efficacy and toxicity. One underappreciated
characteristic of many disease states is that they are often at a lower oxygen tension that normal
tissue (a condition known as hypoxia). Not only is this the case for cancer, but it is thought to be
one of the main reasons why cancer treatment fails. Furthermore, cancer can experience two
types of hypoxia: chronic (sustained low oxygen tension) or intermittent (varying cycles of
hypoxia and normoxia). In both conditions, the vasculature determines the spatial and temporal
dynamics of oxygen. If the tumor cells expand far enough away from the vasculature, this
diffusion-limited oxygen condition will lead to chronic hypoxia. On the other hand, if the tumor
cells encourage rapid vasculature growth that tends to be tortuous and leaky, then this will lead
to intermittent hypoxia. Under both hypoxic conditions, tumor cells upregulate hypoxia inducible
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factor 1α (HIF-1α), a transcription factor which affects many downstream processes that
encourages cell survival. In this dissertation, we investigate our ability to use a microfluidic
platform to mimic some of these key features in the hypoxic tumor microenvironment and test if
it can recapitulate some known biological responses.
First, we created a microfluidic device that can control both spatial and temporal
gradients of oxygen via an oxygen scavenger line. As tumor angiogenesis is a major concern
during tumor progression, we examined angiogenesis in the device. Vasculature was grown in
the central chamber of the device, and stromal cells were grown in compartments on both sides
of the vasculature. Lastly, the oxygen scavenger was flown in a channel adjacent to the left
stromal chamber to create an oxygen gradient across the device. By controlling the flow the of
oxygen scavenger, we could simulate both chronic and intermittent hypoxia. Our results
demonstrate that stromal cells under hypoxia conditions encourage biased angiogenesis, which is
in agreement with previous studies.
Second, using our microfluidic device platform, we investigated how knocking down HIF-1α
affects the survival and progression of breast cancer cells (MDA-MB-231) under various oxygen
gradients. By varying the scavenger concentration, we found a threshold for chronic hypoxia that
the knockdown cells could no longer survive. Interestingly, by modulating the length of the
hypoxic and normoxic cycles during intermittent hypoxia, we could dictate tumor cell survival.
This result emphasizes the importance of understanding the temporal variations of oxygen,
especially with cancer treatments that target HIF-1α.
Altogether, our results further our understanding of how to control spatial and temporal oxygen
gradients for disease modeling. Hopefully with this understanding, future studies will be able to
more effectively assess drug efficacy.
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Chapter 1: Background and Motivation
Cancer is the second leading cause of death in the United States of America behind heart
disease.1 While the number of deaths from heart disease has decreased ever since 1985, the
number of deaths from cancers has nearly tripled since 1960.2 In addition, it has been estimated
that the National Cancer Institute (NCI) alone receives more than $5 billion dollars in
government funding yearly.3 However, there has yet to be a cancer treatment that is effective for
all patients. Meanwhile, the cost of developing a pharmaceutical drug is on the rise; the current
estimate is $1.3 to $2.6 billion to develop a single drug approved by the US Food and Drug
Administration (FDA).4,5 One solution to curb the rising development costs is to create better
models for drug testing.5
There are many difficulties associated with mimicking the tumor microenvironment. Perhaps the
most important is the shear complexity of the tumor microenvironment; that includes an array of
cell types. For example, there is close interaction between the growing tumor and vasculature.
While angiogenesis remains quiescent for the most part in adults, in tumor progression, the
“angiogenesis switch” remains on constantly.6 This is because the rapidly growing tumor
requires nutrients and oxygen as well as to discard metabolic byproducts and carbon dioxide.
Furthermore, access to a vascular network provides tumor cells a method for intravasation and
metastasis.7 These instances are of particular interest to study because the five-yea survival rate
of patients with breast cancer metastasis drop dramatically to 22%.8
To promote tumor angiogenesis, as the tumor grows, it further depletes oxygen via cellular
consumption. This condition of low oxygen (hypoxia) is often associated with poor patient
outcome.9 While a normal tissue response is cellular necrosis, cancer cells have developed an
1

adaptive mechanism that allows them to thrive in hypoxia.10 In addition, advanced cancer is
typically associated with an oxygen tension that is much lower than normal physiology.10 Under
this condition, cancers tend to resistant to traditional cancer treatments such as chemotherapy and
radiotherapy. This effect has largely been attributed to the stabilization of transcriptional
regulator, hypoxia-inducible factor 1-alpha (HIF-1α).11 In cancer biology, this transcription
factor is often dysregulated and overexpressed. Thus, one strategy to develop effective cancer
treatments in a more efficient manner is to replicate this hypoxia microenvironment during drug
testing.9
There are several reasons why it is difficult to replicate the oxygen gradients in the tumor
microenvironment. First, normal physiology is around 5% O2, the hypoxic tumor
microenvironment can be less than 1% O2, and atmospheric oxygen is about 20% O2.12 This
means that cell cultures grown at atmospheric oxygen are experiencing hyperoxia. Second, some
research groups choose to set their incubators to a hypoxic oxygen tension, such as 1% O2.
However, this approach does not have the ability to create and control spatial oxygen gradients
that are present in normal physiology.13 Lastly, another strategy to studying hypoxia is to use a
compound such as cobalt chloride that will stabilize HIF-1α during normoxia.14,15 While this
makes working with the cell cultures easier, it limits the study to only those signaling
mechanisms that are downstream of HIF-1α. In addition, this method also does not replicate the
oxygen gradients are present during tumor progression.
Furthermore, while few studies observe the effects of true hypoxia, most only focus on chronic
hypoxia (sustained low oxygen tension) and not intermittent hypoxia (cycles of hypoxia and
normoxia). However, it has been hypothesized that intermittent hypoxia is more representative of
the tumor microenvironment due to the abnormalities of the vasculature due to rapid
2

angiogenesis.16 However, this phenomenon has been severely underappreciated due to the
difficulties in not only controlling the spatial distribution of oxygen, but the temporal distribution
as well.
One potential solution to recapitulating the oxygen dynamics of the tumor microenvironment is
to use microfluidic devices. Typically, this type of device will have a scavenger channel
dedicated to introducing an oxygen scavenger near the tumor culture chamber. This creates an
oxygen sink that will draw oxygen away from the tissue culture. Additionally, due to their
inherently small size, diffusion is rapid allowing specified oxygen gradients to be precisely
controlled spatially and temporally. This type of platform allows for growing 3D cell culture as
well as the ability to include different cell types. By utilizing these aspects of microfluidic
devices, the microenvironment during tumor progression can be closely recapitulated.
The dissertation contains 4 subsequent chapters. Chapter 2 overviews the current trends and
technologies of tumor hypoxia systems, with an emphasis on tumor development. Chapter 3
focuses on the development of a microfluidic devices to manipulate oxygen tensions within a 3D
tissue to study hypoxia induced angiogenesis. Chapter 4 examines the role of HIF-1α in tumor
cells during spatial and temporal variations in hypoxia. Lastly, chapter 5 remarks on future
advances that can significantly advance the current state of studying tissue hypoxia.
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Chapter 2: Hypoxia and Tumor Angiogenesis
2.1 Overview
The deficiency of oxygen, an essential nutrient for cell proliferation and survival, is a critical
stimulus for acquiring new blood vessels. Hypoxic tumors activate molecular programs that lead
to secretion of proangiogenic factors by the tumor as well as tumor-associated stromal cells.
Tumor hypoxia has been associated with poor patient prognosis, with clinical studies showing
that advanced breast cancers have a median oxygen tension of 10 mmHg, compared with 65
mmHg in normal breast tissue.10,17,18 Hypoxic cores exist in advanced stage tumors,19 and can
also exist in tumors as small as 400 m in diameter.20 In hypoxic conditions, angiogenesis is
primarily regulated by hypoxia inducible factors (HIFs). Of the highly conserved HIF family of
transcription factors, HIF-1 has been the best studied.11,21,22 It is known to be a heterodimer of αsubunit (HIF-1α) and a β-subunit (HIF-1β), where subunits are members of the basic helix-loophelix (bHLH)-containing PER-ARNT-SIM (PAS) domain family of transcription factors. In
addition to HIF-1α and HIF-1β, there are two additional oxygen regulated α-subunits are (HIF2α and HIF-3α) and two other constitutively expressed β-subunits (HIF-2β, and HIF-3β).
Furthermore, the low oxygen environment stabilizes HIF-1α in endothelial cells as well.23
The HIF-1 activation follows a series of molecular events. Starting at oxygen concentrations
below 6%, HIF-1α stabilizes and translocates from the cytoplasm to the nucleus, where it
dimerizes with HIF-1β.24 HIF-1 then binds to hypoxia responsive elements (HREs) within the
promoters of HIF target genes leading to the increased expression of proangiogenic factors such
as vascular endothelial growth factor (VEGF), VEGF-R2, angiopoietin 1/2, fibroblast growth
factor, platelet-derived growth factor, and the decreased expression of anti-angiogenic factors
4

such as thrombospondin-1 and carbonic anhydrase-9.25 In addition to angiogenesis, HIF-1 can
activate more than a hundred genes that control important cellular processes such as epithelialmesenchymal transition, stem-cell maintenance, and metabolism that impact tumor cell invasion,
metastasis, metabolic reprograming, and resistance to therapy.22

2.2 Controlling and Measuring Oxygen in vitro
The traditional method to create hypoxic conditions utilizes cell culture incubators, where
blending excess nitrogen with air lowers oxygen concentration. Alternatively, the exchange of
oxygen from air can be controlled by an air tight glove box equipment, or hypoxic conditions can
simply be generated due to consumption of oxygen by cell culture. Additionally, chemicals that
consume oxygen, such as sodium nitrate, can also be used to manipulate oxygen tension.12
Alternatively, cobalt chloride can stabilize HIF-1α in the presence of normoxia, and allows for
more flexible data collection. This “pseudo-hypoxic” condition can simulate the impact of HIF1α, but cannot fully recapitulate all features that hypoxia has on cell function.15
Microfluidic devices have become attractive systems to study hypoxia due to their inherently
small size, and thus small diffusion distances. A common technique to reduce oxygen in
microfluidic devices is to use separate channels containing an oxygen scavenger such as sodium
nitrate (Fig. 2. 1A). These channels are separated from the tissue chambers by a semipermeable
material, such as PDMS, that allows diffusion of oxygen but not water.26–28 By altering the
concentration and flow of the scavenger, the oxygen tension within the device can be controlled
with high spatial and temporal resolution. PDMS is ideally suited as a material of construction
for these device as it is a highly permeable material with respect to oxygen compared to
relatively impermeable materials such as cyclic olefin copolymer, polystyrene, polypropylene,
poly(methacrylic acid), polyurethane, and poly(methyl pentene).29 By choosing an appropriate
5

coating and/or using an oxygen scavenger, a wide range of oxygen concentrations can be
controlled to study tumor hypoxia and its effects.
A major advantage of using in vitro systems is that real time oxygen measurements can be
performed in a live tissue culture with minimal disruption of biological processes. The gold
standard for the oxygen sensors is Clark-type electrodes which measure oxygen by detecting a
current flow caused by the reduction of oxygen.30 However, the method is operationally complex
and less sensitive for oxygen measurement relative to other methods. Recently, more sensitive
techniques have been developed that employs an oxygen sensitive luminophore. The
luminescence of oxygen sensitive dyes is inversely proportional to the concentration of oxygen.
When the dyes are excited by a laser in the presence of oxygen, the excited state energy of the
phosphorescent indicator molecule is absorbed by oxygen instead of being emitted as a
luminescent photon. In other words, oxygen quenches the phosphorescence, and reduces the
lifetime of the phosphorescence decay. Generally, a shorter luminescence lifetime indicates a
higher oxygen concentration. The lifetime of the phosphorescence, as opposed to the intensity, is
a more robust method as it is insensitive to photobleaching and independent of the concentration
of the dye. Detecting the luminescence lifetime generally requires a more complicated
experimental setup because a pulsed laser needs to be used (Fig. 2. 1B).31

6

Fig. 2. 1 (A) Oxygen scavenger lines can be designed into microfluidic platforms to generate hypoxic conditions inside tissue
chambers. Typically these include materials such as sodium sulfite. (B) PhLM is a method used to measure oxygen
concentrations in 3D culture systems. Using a pulsed laser to excite the oxygen sensitive dye and measuring the dye’s lifetime
of decay, a longer phosphorescent lifetimes correspond to lower oxygen concentrations.

While many research groups have focused on controlling the oxygen environment around tumor
spheroids, some groups, including ours, have begun to control oxygen tension in vascularized
tumors.26,27,32 Due to the role that the vascular network has in oxygen regulation and the
interaction between the tumor and the vasculature during hypoxia, the inclusion of these
components in the next generation of tumor organoid models is critical for a complete
understanding of angiogenesis in the tumor microenvironment.

7

Chapter 3: Microfluidic device to attain high
spatial and temporal control of oxygen
3.1 Abstract
Microfluidic devices have been successfully used to recreate in vitro biological
microenvironments, including disease states. However, one constant issue for replicating
microenvironments is that atmospheric oxygen concentration (20% O2) does not mimic
physiological values (often around 5% O2). We have created a microfluidic device that can
control both the spatial and temporal variations in oxygen tensions that are characteristic of in
vivo biology. Additionally, since the microcirculation is responsive to hypoxia, we used a 3D
sprouting angiogenesis assay to confirm the biological relevance of the microfluidic platform.
Our device consists of three parallel connected tissue chambers and an oxygen scavenger
channel placed adjacent to these tissue chambers. Experimentally measured oxygen maps were
constructed using phosphorescent lifetime imaging microscopy and compared with values from a
computational model. The central chamber was loaded with endothelial and fibroblast cells to
form a 3D vascular network. Four to six days later, fibroblasts were loaded into the side
chambers, and a day later the oxygen scavenger (sodium sulfite) was flowed through the adjacent
channel to induce a spatial and temporal oxygen gradient. Our results demonstrate that both
constant chronic and intermittent hypoxia can bias vessel growth, with constant chronic hypoxia
showing higher degrees of biased angiogenesis. Our simple design provides consistent control of
spatial and temporal oxygen gradients in the tissue microenvironment and can be used to
investigate important oxygen-dependent biological processes in diseases such as cancer and
ischemic heart disease.
8

3.2 Introduction
Although hypoxia, or low oxygen tension, is a central feature of many different diseases, it is
also a part of normal physiological states.10,25,33 Hypoxia can be chronic (sustained oxygen
tension < 5% O2 for > 24 hours), as in the case of ischemic heart disease and wound healing, or
intermittent (repeated oxygen tension <5% O2 for < 24 hours) as in the case of some tumors,
sleep apnea, and exercise.34–37 Moreover, diseases such as cancer can exhibit both chronic
hypoxia and intermittent hypoxia states which can affect different processes of tumor
progression. The rapid rate of diffusion of abundant oxygen in gas and liquid systems has made
it difficult to experimentally study the impact of hypoxia at small spatial scales, in particular, to
replicate in vivo intermittent hypoxia conditions. The presence of atmospheric air (ambient pO2
is around 160 mmHg or 20% O2) provides a regular source of “contamination” as normoxia or
physiological oxygen concentration for tissues are on average about 38 mmHg or 5% O2.
Although previous literature has defined normoxia as 20% O2, we choose to define it as 5% O2
because it is more physiologically relevant. Although the incubator oxygen tension may be set to
5% O2, controlling the spatial distribution of oxygen within the cell culture is not possible. As
the tissue expands farther away from the vessel network, an oxygen gradient is established, with
the cells farthest away experiencing the lowest oxygen tension. In addition, it has been shown
that gradients are important for chemical and mechanical factors for recapitulating the
physiological microenvironment.38,39
Here, we present a microfluidic device that can precisely control oxygen tension over spatial and
temporal dimensions on the order of microns and minutes, respectively. This level of control
permits the interrogation of physiologically relevant hypoxia in a wide range of normal and
diseased tissues. Our strategy leverages the small dimensions of microfluidic devices that
9

minimize the distance of diffusion for oxygen to control precise gradients. Microfluidic systems
provide faster oxygen cycle switching than some commercial systems, (e.g., Eppendorf Galazy
48R), which can take up to 30 minutes to equilibrate to a new oxygen concentration. In addition,
previous methods of studying hypoxia in microfluidic devices often involve nearby channels to
flow nitrogen gas to create an oxygen sink.26,40,41 While this can create controlled oxygen
gradients, the need for nitrogen tanks is cumbersome. Furthermore, the use of a compressed gas
can introduce bubbles and pervaporation in the culture chambers, which can compromise the
experimental conditions.
Our approach utilizes a simple and inexpensive aqueous solution of sodium sulfite as an oxygen
scavenger to reduce pervaporation and cost while still maintaining high spatial and temporal
control of oxygen. This easily prepared solution is flowed in a fluidic channel running parallel to
the tissue chambers. Because this channel is not connected to the tissue chambers the oxygen
scavenger will not produce any unwanted side effects to the tissues. Moreover, most in vitro
studies mimic intermittent hypoxia cycle between 20% and 1% O2 to ensure two different
oxygen states.42–44 However, 20% O2 is representative of hyperoxia and does not accurately
represent in vivo intermittent hypoxia. Subsequently, because we can measure the spatial and
temporal oxygen distribution within our device, we can easily switch between the more
physiological concentration of 5% and 1% O2. Thus, we believe that our results more accurately
represent physiological response to intermittent hypoxia. Furthermore, although previous studies
have shown the effects of using an oxygen scavenger in a 20% O2 incubator the range of oxygen
concentrations often go far above physiological values.45
To demonstrate the biological relevance of our microfluidic system, we used an in vitro model of
angiogenesis. During hypoxia, new blood vessels can sprout from existing vessels (angiogenesis)
10

as a normal biological response to relieve hypoxia by increasing blood flow and delivering
oxygen. On the other hand, hypoxia can also lead to necrosis of the tissue if there is a failure to
encourage new vessel growth. These two drastically different outcomes are both possible during
hypoxia because both pro-angiogenic and anti-angiogenic genes can be activated, and this
balance dictates the outcome.46 Thus, it is important to determine the subtleties of spatial and
temporal variations in oxygen and how this can bias vessel growth. Our theoretical and
experimental results demonstrate spatial and temporal control over the oxygen tension within a
microfluidic platform. In addition, the simple and flexible design will prove useful for a range of
additional biological applications. In this study we show the effects of normoxia (N), constant
chronic hypoxia (CH), and intermittent hypoxia (IH) on true 3D angiogenesis.

3.3 Materials and Methods
3.3.1 Design and microfabrication of microfluidic device
The microfluidic device design has three parallel chambers connected through capillary burst
valves measuring 30 μm wide and 100 μm high to facilitate communication between chambers
(Fig. 3. 1A). The central compartment (vascular chamber) is the largest with a volume of 0.06
mm3 (1.5 mm x 0.4 mm x 0.1 mm), and the two adjacent chambers are smaller with a volume of
0.02 mm3 (0.8 mm x 0.25 mm x 0.1 mm). Only the central compartment has media lines that are
connected through capillary burst valves on each end. This design allows for separate chambers
to contain different compositions of cells and extracellular matrix as well as to be loaded into the
device at different time points. The two media lines were designed to control the flow of media
via a difference in hydrostatic pressure head between the two lines. The flow was controlled to
mimic physiological fluid velocities of approximately 1-10 μm s-1. Lastly, microfluidic channels
adjacent to each of the smaller tissue chambers are present and are used to deliver the oxygen
11

scavenger to create the oxygen gradient. The microfluidic device design has three parallel
chambers connected through capillary burst valves measuring 30 μm wide and 100 μm high to
facilitate communication between chambers (Fig. 3. 1A). The central compartment (vascular
chamber) is the largest with a volume of 0.06 mm3 (1.5 mm x 0.4 mm x 0.1 mm), and the two
adjacent chambers are smaller with a volume of 0.02 mm3 (0.8 mm x 0.25 mm x 0.1 mm). Only
the central compartment has media lines that are connected through capillary burst valves on
each end. This design allows for separate chambers to contain different compositions of cells and
extracellular matrix as well as to be loaded into the device at different time points. The two
media lines were designed to control the flow of media via a difference in hydrostatic pressure
head between the two lines (Fig. 3. 1B). The flow was controlled to mimic physiological fluid
velocities of approximately 1-10 μm s-1. Lastly, microfluidic channels adjacent to each of the
smaller tissue chambers are present and are used to deliver the oxygen scavenger to create the
oxygen gradient.

B

A

500 μm

Fig. 3. 1 Microfluidic Device Schematic. (A) The design of the microfluidic device with the central vascular
chamber (yellow) and adjacent stromal chambers (brown). Scavenger channels (blue) are placed next to the stromal
chambers and media lines (red) feed the vascular chamber. (B) Experimental setup for the microfluidic devices. A
difference in hydrostatic pressure head between the inlet and outlet of each microfluidic line creates a drop in
pressure between the two sides of the vascular chamber to induce convective interstitial flow throughout the device.
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Once a computer-aided design (CAD) of the device was created, the design was printed and
standard photolithography methods were used to build the device. Briefly, a negative photoresist,
SU-8 3050, (MicroChem, Newton, MA) was spun onto a silicon wafer to a height of 100 μm.
Ultraviolet light exposure crosslinked the pattern of the device into the photoresist. After the
pattern on the wafer was developed, the mold was silanized and polydimethylsiloxane (PDMS;
Dow Corning, Elizabethtown, KY) was poured over the mold at a mixture of 10:1 (w/w)
polymer to curing agent. The PDMS was cured in a 65 °C oven overnight. The PDMS was then
peeled off the mold and the inlet and outlet holes were punched into the device using an 18
gauge needle for the tissue chambers and 16 gauge needle for the media and scavenger lines. To
bond the PDMS device to a glass slide, both pieces were first cleaned to remove debris and then
plasma treated for 1 minute at 250 mTorr. After plasma treatment, the PDMS device was sealed
to the glass slide and placed in a 120 °C oven for a minimum of 15 minutes. Lastly, the device
was sterilized with ultraviolet light before experimentation.

3.3.2 Numerical Simulations
To enhance our understanding of interstitial flow and oxygen concentrations within the device,
we created a computational model of mass and momentum transport using COMSOL
Multiphysics® 5.2a (Burlington, MA) combined with the CAD model of the device. To simulate
the flow throughout the device, a 3D steady state solution of the incompressible Navier-Stokes
equations was calculated using no slip boundary conditions for all the walls. Properties of the
components of the device are listed in Table 3. 1 and are consistent with previous work. The
transport of diluted species module was used to model the oxygen gradients throughout the
device. Initial conditions for oxygen concentrations was set to 5% O2. Using Henry’s law, the
outer boundaries of the device (PDMS-air interface) were set using the incubator level of 5% O2,
13

and a Michaelis-Menten kinetic equation was used to simulate cellular metabolism of oxygen.47
The PDMS-media interface was modeled using a pointwise constraint at the boundary in
accordance with the stiff-spring method.48 A media/PDMS partition coefficient of 0.18 was used
in the model. The consumption of oxygen through the reaction with sodium sulfite (Na2SO3) was
used from previously reported findings in the literature.47,49–54 In brief, 1 mole of oxygen (O2)
reacts with 2 moles of sodium sulfite (Na2SO3) to produce 2 moles of sodium sulfate (Na2SO4)
with a reaction rate constant, k (Table 3. 1):

(Eq. 1)

Parameter

Value

Unit

Source

Inlet pressure (high side)

25

mmH2O

-

Outlet pressure (high side)

0

mmH2O

-

Inlet pressure (low side)

10

mmH2O

-

Outlet pressure (low side)

0

mmH2O

-

Fibrin permeability

1.5E-13

m2

22

Diffusion of oxygen through PDMS

3.55E-9

m2 s-1

25

Max rate of oxygen metabolism by cells (Vmax)

1.3E-17

mol s-1

18

Oxygen consumption at half of Vmax (KM)

.008

mol m-3

18

Reaction rate constant (k)

5.77E-5

M0.35 s-1

24

Partition coefficient

0.18

-

19

Table 3. 1 List of Model Parameters.

Opposite the oxygen scavenging channel is a channel open to the atmosphere of the incubator,
and thus set to 5% O2. The computational mesh of the model consists of 700,000-1,000,000
tetrahedral grid elements. For the intermittent hypoxia simulations, time dependent simulations
were used with hour cycles of flowing and stopping the reaction with sodium sulfite. To
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demonstrate the ability of the device to manipulate the gradient and oxygen tension, additional
conditions were modeled to create several unique oxygen profiles. The simulated conditions
(Table 3. 2) include modifying the constant chronic hypoxia condition (CH) to having a reduced
mass flow rate of the scavenger in the device (rCH), increased wall thickness between the
scavenger channel and tissue chambers (wCH), and two scavenging lines (2CH). These
modifications were added to demonstrate the versatility of oxygen gradients available with our
device.
Condition

Mass Flow
Rate (mol s-1)

N
IHon
IHoff
CH
rCH
wCH
2CH

0
2 x 10-6
2 x 10-6
0.7 x 10-6
0.07 x 10-6
0.7 x 10-6
0.7 x 10-6

Wall
Thickness
(μm)
30
30
30
30
60
30

Number of Active
Scavenger Lines

Frequency
(h-1)

Time during
cycle (min)

0
1
1
1
1
1
2

0.5
0.5
-

Constant
60
60
Constant
Constant
Constant
Constant

Table 3. 2 List of Experimental Conditions. N: Normoxia; IHon: Intermittent hypoxia while 2 x 10-6 mol s-1
Na2SO3 is flowing for an hour; IHoff: Intermittent hypoxia while scavenger stopped flowing for an hour; CH:
Constant chronic hypoxia of flowing 0.7 x 10-6 mol s-1 Na2SO3; rCH: Constant reduced mass flow rate of oxygen
scavenger flowing at 1/10th the speed of CH; wCH: Constant hypoxia with increased thickness of the PDMS wall
between the scavenging channel and tissue chamber; 2CH: Constant hypoxia with two active scavenger line

3.3.3 Oxygen Measurements
To validate the oxygen concentration predictions from the computational model, we used
phosphorescent lifetime imaging microscopy (PhLIM) that utilizes an oxygen sensitive dye,
Oxyphor G4 (Oxygen Enterprises, Philadelphia, PA).31,55 This Pd-tetrabenzoporphyrin based dye
is based on phosphorescence quenching, and we have already demonstrated its proficiency in an
in vivo model.56 To excite the phosphorescent dye, we used a 635 nm laser to modulate at 1 kHz
with 5% duty cycle (FV1200 Olympus confocal with ISS (Urbana-Champagne, IL)
phosphorescent lifetime instrumentation upgrade). The emission beam was collected through a
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miniTDU that was equipped with two Hamamatsu 7422p-50 detectors, which was coupled
directly to the confocal head. To perform the oxygen measurement, the dye was added to the
media of the device at a concentration of 20 μM after the end of the cellular experiment. The dye
was allowed to equilibrate for at least an hour through the fibrin and tissue in the device. Oxygen
measurements were made over the entire area of the three chambers for each of the three
experimental conditions. The phosphorescent lifetime of each pixel was calculated and was then
converted into oxygen tension using a previously determined calibration curve at 22 oC. 31 The
advantage of using the PhLIM technique with Oxyphor G4 is that experimental measurements at
high spatial and temporal resolution can be achieved.

3.3.4 Cell Culture
As previously described by our lab 57,58, endothelial colony forming cell-derived endothelial cells
(ECFC-EC) were derived from cord blood and seeded on 1% gelatin-coated (Sigma-Aldrich, St.
Louis, MO) flasks and provided with endothelial growth medium-2 (EGM-2; Lonza,
Wakersfield, MD). Normal human lung fibroblasts (NHLF) were commercially purchased and
grown in fibroblast growth media (FGM-2, Lonza) before use in the experiments. All cells were
cultured in a humidified incubator at 37 °C, 5% CO2, and 20% O2 before loaded into the
microfluidic device.
To study angiogenesis in the presence of spatial oxygen gradients, transduced ECFC-ECs that
constitutively express fluorescence were used to continuously monitor growth of new blood
vessels. To transduce the cells, we used a lentiviral particle titer from a human embryonic kidney
primary cell line (HEK293T Cells, ATCC, Manassas, VA). The HEK293T cells were seeded in a
6 well plate at a density of 5.0 x 105 cells/well and incubated for 24 hours in Dulbecco’s
Modified Eagle Medium (DMEM, ThermoFisher, Waltham, MA) containing 10% fetal bovine
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serum (FBS, Sigma-Aldrich, St. Louis, MO) and no antibiotics. A solution of 250 μL of Opti
MEM (Invitrogen, Carlsbad, CA), 7.5 μL of Lipofectamine 2000, and 3μg of plasmid DNA (1.5
μg pLVX-Azurite, .75 μg pMDLg/pRRE, .3 μg pRSV-Rev, and .45 μg pMD2.G) was mixed and
incubated for 25 minutes at room temperature. Then, 500 μL of the solution was added dropwise
to the wells of the HEK293T cells. The contents of each well was replaced with fresh media 24
hours later. After 48 hours of incubation, the viral supernantant was collected and spun down to
exclude cell debris and stored at -80 °C. A T-150 flask of ECFC-ECs were seeded and grown
until about 30-40% confluency. Then, a 25 mL solution of EGM containing 8 μg/mL polybrene
(Santa Cruz Biotechnology, Dallas, TX) and 500 μL of viral titer was added to the cells and
allowed to incubate for 24 hours at 37 °C. The contents of the flask were then aspirated and fresh
EGM was added. Transduction efficiency was measured to be more than 90%.

3.3.5 Device Experimentation
For the vascular chamber, ECFC-ECs and NHLFs were trypsinized and resuspended in 16 mg
mL-1 bovine fibrinogen (Sigma-Aldrich, St. Louis, MO) dissolved in Dulbecco’s Phosphate
Buffered Saline (DPBS; ThermoFisher). The ECFC-ECs were collected at 5 x 106 cells mL-1 and
the NHLFs were collected at 10 x 106 cells mL-1. Thrombin (Sigma-Aldrich) was prepared to a
concentration of 50 U mL-1 in DPBS and added to the cell-fibrinogen solution. This initiated the
polymerization process, and the solution was quickly pipetted into the central or vascular
chamber of the device. After incubating the gel for 30 minutes at 37 °C, EGM-2 was added to the
media lines for the first 24 hours of the experiment and flow was maintained using a hydrostatic
pressure head. Afterwards, the devices were placed in a 37 °C, 5% CO2, and 5% O2 incubator
and EGM-2 without growth factors was used to feed the tissue. The direction of the pressure
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gradient throughout the device was switched every day to ensure spatially homogenous growth.
59,60

Following the first four days of the experiment, vascular structures were apparent, and the
adjacent chambers were then loaded with fibroblasts in a fibrin gel at a concentration of 7.5 x 106
cells mL-1 using the previously described method. After 24 hours, the oxygen scavenger, sodium
sulfite (Sigma Aldrich, St. Louis, MO), was dissolved in deionized water and pushed through the
left scavenger channel of the device using a syringe pump. Only one of the scavenging channels
had an oxygen scavenger flowed through it. The other channel (farthest right channel) was kept
open to atmosphere to keep the right tissue chamber close to normoxia. Tygon tubing (SaintGobain, Valley Forge, PA) was used to connect the sodium sulfite syringes with the devices. To
ensure that the two hypoxia conditions had the same average oxygen concentration over the
duration of the experiment, 0.35M sodium sulfite was flowed at 120 μl min-1 (mass flow rate of
0.7 x 10-6 mol s-1) continuously for the CH condition while 1 M flowed at 120 μl min-1 (mass
flow rate of 2 x 10-6 mol s-1) was used for the IH condition with the pump programed for 1 hour
of scavenger flow (IHon) and 1 hour of no flow (IHoff). To mimic CH and IH, sodium sulfite was
introduced through the left side of scavenger line for 6 more days until the end of the duration of
the experiment. Because sodium sulfite constantly reacts with oxygen, it was important to
maintain a constant flow of oxygen scavenger.

3.3.6 Quantification of Biased Angiogenesis
At the end of the experiment, images were taken of the fluorescent vascular network in each of
the chambers. To quantify sprouting angiogenesis, images were cropped to only contain the left
or right stromal chamber. The images were randomized and blinded for image analysis in
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ImageJ. Multiple devices were used for each condition of N (n=8), CH (n=11), and IH (n=17).
We calculated biased angiogenesis using the following relationship:

(Eq. 2)

In other words, the vessel area in each side chamber is expressed as the fraction of total
angiogenesis into both chambers. A value of 0.5 indicates unbiased angiogenesis.

3.3.7 Statistical Analysis
Because the data was not normally distributed, the parameters are presented with medians and
ranges from the 25% to 75% percentile. To determine if the biased angiogenesis and vessel area
in the left chamber was significantly different compared to the right chamber, a nonparametric
Mann-Whitney test was applied using GraphPad Prism. Significance was determined at the p <
0.05 level.

3.4 Results
3.4.1 Microfluidic Device: Pressure and Flow
After successful construction of the microfluidic device, we demonstrated desired pressure and
velocity profiles (Fig. 3. 2A-B). The steady pressure profile of the device (Fig. 3. 2A)
demonstrates a drop in pressure in the vascular chamber to the stromal chambers from 1 x 10-2
mmH2O to 0.5 x 10-2 mmH2O (approximately 9.8 x 10-2 to 4.9 x 10-2 Pa), respectively, with the
stromal chamber averaging 0.85 x 10-2 mmH2O (8.3 x 10-2 Pa). Additionally, the device was
designed to create physiologically relevant fluid velocities ranging between 1-10 μm s-1 by
appropriately adjusting the hydrostatic pressure head (25 mmH2O, Fig. 3. 2). Another design
consideration to note is that the adjacent stromal chambers do not have separate media lines; the
chambers receive nutrients through the vascular chamber as shown by the streamlines (Fig. 3.
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2B). To demonstrate this effect in the device, fluorescein isothiocyanate-dextran (FITC-dextran)
was introduced through the media lines to show the direction of fluid flow through the
connecting pores (Fig. 3. 2C).

Fig. 3. 2 Microfluidic Device Characterization. (A) Surface map of the steady pressure (Pa) distributions inside the
3.4.2
Microfluidic
Device:
Concentration
Profiles
microfluidic
device. (B) Surface
map of Oxygen
the fluid velocity
(μm s-1) and streamlines.
(C) FITC-dextran was
introduced
through the condition
media lines was
to demonstrate
direction
flow throughand
the device
(bottom to top
Each
experimental
modeledthe
using
a 3Dofsimulation,
2D projections
areand
shown
central chamber to outside chambers). The image was taken 30 minutes after introducing the dye. Scale bar = 200
μm.
from a slice of the model in the xy plane 50 μm from the bottom of the device (plane at vertical

center). In addition, a horizontal line (represented by a white arrow) was drawn in the middle of
the chambers to quantify the gradient across the device (Fig. 3. 3A-C, top row). With no
scavenger present (N condition) the oxygen concentration remains constant near 5% O2
throughout the device (Fig. 3. 3A, top, and Fig. 3. 3E). Although the device is fairly symmetric,
the placement of the media lines on the left side of the central chamber (Fig. 3. 1A) raises
oxygen tension slightly in the left stromal chamber. The CH condition (0.7 x 10-6 mol s-1 sodium
sulfite) created a steady state oxygen gradient from 3.2% O2 in the left chamber to 4.6% O2 in
the right chamber (Fig. 3. 3B, top, and Fig. 3. 3E), and a mean concentration of 4% O2 in the
central chamber.
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Fig. 3. 3 Finite Element Simulations and Measurements of Steady State Oxygen Tension. (A-C, top row) Surface maps
of theoretical oxygen tension in different conditions are shown. (A) Normoxic condition (N) with no oxygen scavenger,
(B) constant chronic hypoxia condition (CH) with a constant flow of 0.35 M sodium sulfite flowing at 120 μl min -1, and
(C) intermittent hypoxia (IH) condition of alternating 1 M sodium sulfite flowing at 120 μl min -1 for an hour (IHon, left
panel) and no flow of oxygen scavenger for an hour (IHoff, right panel). (A-C, bottom) Experimental oxygen maps were
constructed using a PhLIM technique for the N (A, bottom), CH (B, bottom), and IH (C, bottom) conditions. The IH on
measurements were taken an hour after flowing sodium sulfite, and the IHoff measurements were taken an hour after
stopping flow. (D) Temporal variations of the oxygen tension at a point in the left stromal chamber from the COMSOL
model in (C, top). The asterisks (*) and circle (o) on the oxygen maps corresponds to the low and high points of the
graph, respectively. (E) Comparing the oxygen profiles of all the varying conditions along the central line of the three
chambers (arrow in A-C). The conditions are N (black), CH (red), IH (green). The IH case is represented by a green area
to illustrate the range of oxygen profiles between the two extreme states of the condition. The solid lines are values from
the COMSOL model, and the points are averages from the PhLIM measurements for the three conditions (n=3 for each
conditions).
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The IH condition was designed to have the same average oxygen concentration over time as CH.
After one hour of 2 x 10-6 mol s-1 sodium sulfite flowing through the scavenger line in the IH
condition, the oxygen tension ranged from 1.7% (left) to 4.5% (right) O2 (Fig. 3. 3C, top left,
and Fig. 3. 3E). After one hour of no scavenger flow, the oxygen profile resembled the normoxia
case with the average concentration being only slightly less than 5% O2 (Fig. 3. 3C, top right,
and Fig. 3. 3E). The time averaged mean concentration in the central chamber over a complete
cycle was 4% O2, similar to that of CH. The temporal variations of a fixed position in the middle
of the left chamber is shown by the * and o symbols in Fig. 3. 3C to demonstrate the dynamics
in our device (Fig. 3. 3D). This figure also shows the step function of the flow of oxygen
scavenger going from 120 μl min-1 to no flow. Although the sodium sulfite reacts with oxygen
quickly to lower the concentration, there is a lag to reach the final oxygen concentration (Fig. 3.
3D). In these experiments, we used molar concentrations of sodium sulfite to ensure a zero
concentration of oxygen within the solution. The reaction of sodium sulfite depends only on the
concentration of sodium sulfite and is zero order with respect to oxygen53; thus, the aqueous
solution of sodium sulfite quickly (minutes) depletes all the oxygen before entering the
microfluidic device. This makes sodium sulfite a very effective solution for creating hypoxic
oxygen gradients.
Experimental oxygen measurements were taken once the dye reached equilibrium within the
device. The oxygen maps of the experimental conditions are shown in Fig. 3. 3A-C, bottom,
with the measurements for the intermittent hypoxia condition taken one hour after each cycle
began. The experimental oxygen concentrations (mean top to bottom for each location from the
scavenger) for each condition (Fig. 3. 3E) were in agreement with the simulated values (Fig. 3.
3A-C, top row).
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To illustrate the utility of the microfluidic device for different spatial and temporal oxygen
gradients, we performed three additional simulations (Table 3. 2, Fig. 3. 4). The first condition,
rCH, consisted of reducing the mass flow rate of sodium sulfite to 1/10th the original speed
compared to CH (0.07 mol s-1, Fig. 3. 4A) which increases the oxygen concentration (range of
4.5% to 4.9% O2). Next, the condition wCH manipulated the oxygen profile by changing the
thickness of the PDMS wall that separates the tissue chambers and the scavenger line. By
doubling this wall to 60 μm compared to CH (wall thickness of 30 μm), and using the original
mass flow rate of 0.7 x 10-6 mol s-1, the overall concentration of oxygen was also increased
(range of 3.4% to 4.7% O2, Fig. 3. 4B). Lastly, the condition 2CH drastically changed the
oxygen profile by flowing 0.7 x 10-6 mol s-1 sodium sulfite through both scavenger lines. This
condition lowered the overall concentration of oxygen in the device by scavenging both sides. In
contrast to all previous simulations, the middle chamber had the highest oxygen concentration as
it was the furthest from the scavenger lines. The oxygen tension range in this case was 2.4% to
2.8% O2 (Fig. 3. 4C). The oxygen quantification of each condition is shown in Fig. 3. 4D and
represents the concentration of oxygen at each distance along the middle of the chamber (arrow
in Fig. 3. 4A-C). As with the previous simulations, because of the subtle asymmetry of the
device, the oxygen gradient is not perfectly symmetric although the two scavenger lines have the
same mass flow rate of sodium sulfite. The simulations show a range of oxygen tensions that can
be achieved by varying parameters such as oxygen scavenger concentration, time exposed to an
oxygen scavenger, flow rate of the oxygen scavenger, membrane wall thickness, and number of
active scavenger lines.
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Fig. 3. 4 Varying Device Parameters. (A) Reduced mass flow rate condition (rCH) with 0.07 x 10-6 mol s-1 of
sodium sulfite. (B) Increased wall distance (wCH) between the scavenger channel and stromal chamber to 60 μm.
(C) Two active scavenger lines (2CH). (D) Comparing the oxygen profiles of all the varying conditions along the
central line of the three chambers (arrow in A-C) with the experimental conditions from Fig. 3. The conditions are N
(black), CH (red), IH (green), rCH (yellow), wCH (purple), and 2CH (blue).

3.4.3 Angiogenesis within the three-chambered device
The ECFC-ECs and NHLFs in the central chamber were allowed to grow in a fibrin gel
independently for the first four days of the experiment until early vasculature structures were
apparent. On day 4, NHLFs in a fibrin gel were loaded into the adjacent left and right chambers,
and after 24 hours of incubation, the NHLFs began to spread and resume normal fibroblast
morphology. Sprouting vasculature into the left and right stromal chambers was apparent after 6
days.
At the end of the experiment, each condition had devices that sprouted vessels into the adjacent
chambers. Fig. 3. 5A shows representative images of the three conditions at the start (left panels)
and end (right panels) of the experiment. After images of the left and right chambers were
randomized and blinded for image analysis, parameters of vessel area and angiogenesis bias were
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calculated. In the N condition, the left chamber had an average area of 35,577 (8,034 – 46,742)
μm2 and the right chamber had an average area of 40,582 (10,109 – 62,537) μm2. This generated
values for angiogenesis bias of 0.45 (0.18 – 0.65) and 0.55 (0.35 – 0.82) for the left and right
chambers, respectively, which were not statistically significant. In the CH condition, the left
chamber had an average area of 12,606 (1,644 – 14,696) μm2, which was significantly higher
than the right chamber with an average area of 1,187 (167 – 2767) μm2, p < 0.05. This result was
also present in the angiogenesis bias for the left and right chambers which were 0.93 (0.72 – 1.0)
and 0.07 (0.0 – 0.28) respectively (p < .0001). Lastly, the IH case also had significantly different
vessel areas in the adjacent chambers with the left chamber having an average of 4,664 (3,121 –
6539) μm2 and the right chamber having an average area of 1,289 (300 – 4970) μm2, p < 0.05 .
This trend produced an angiogenesis bias of 0.78 (0.51 – 0.96) and 0.22 (0.04 – 0.49) for the left
and right chambers which was statistically significant (p < .0005) (Fig. 3. 5B-C).
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Fig. 3. 5 Biased Angiogenesis Due to Hypoxia. (A) Representative images from the N (top), CH (middle), and IH
(bottom) conditions. In each category, images of the vascular network before (left) and after (right) the condition
was applied is shown. (B) The total vessel area for each category in the left and right stromal chambers were
measured and compared. For both hypoxic conditions, the vessel area in the left stromal chamber (closer to the
scavenger channel) was significantly higher than the right chamber. (C) Biased angiogenesis was calculated for the
left and right stromal chambers in each condition and compared to each other. Both hypoxic conditions had
significantly more bias in the left stromal chamber. N, n=8; CH, n=11; IH, n=17. Scale bar = 200μm * p<.05, **
p<.005, *** p<.0005, **** p<.0001.

We also created control conditions that contained no fibroblasts in the adjacent compartments
(plain fibrin) under normoxic and constant chronic hypoxic conditions. In the normoxic case,
there were no angiogenic sprouts into the adjacent chambers. On the other hand, the device with
plain fibrin in the adjacent chambers had degraded vessels under the constant chronic hypoxic
condition (data not shown).

3.5 Discussion
A promising use of organ-on-a-chip technology is the ability to mimic and test disease states.
Hypoxia is a prominent feature of diseases such as wound healing, ischemia, and cancer. Hence,
the ability to control oxygen within a microfluidic device provides a unique opportunity to
understand the impact of oxygen tension at high spatial and temporal resolution. While common
previous studies may set an incubator to a specific oxygen concentration, this does not create the
oxygen concentration gradients that are relevant to human physiology. The structure of the
microcirculation is sensitive to oxygen tension, and our device design demonstrates the ability to
spatially (microns) and temporally (minutes) control the oxygen concentration around a steady
vascular network to study these effects. Our device can introduce various combinations of cells
and extracellular matrix at different time points as well as manipulate the oxygen concentration
to simultaneously compare the effects of a normoxic and hypoxic stromal chamber on a
neighboring vascular network.
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Our ability to experimentally measure oxygen within the device provides the opportunity to
validate the performance and accuracy of the platform and model simulations. PhLIM provides
high spatial resolution in 3D that is capable of capturing an entire oxygen map. This is a distinct
advantage over traditional oxygen sensors and probes that are placed on one surface or in a
single position and rely on models to extrapolate the3D oxygen map. The PhLIM oxygen
measurements closely match the oxygen values predicted by the model over a range of
experimental conditions.
While other intermittent hypoxia studies typically switch between 20% and 1% O2 42–44, it is
physiologically more relevant to cycle between 5% and 1% O2 to replicate disease states such as
the tumor microenvironment in the presence of leaky vasculature.10 In our simulations and
experiments, we are able to easily produce oxygen values in the 1-5% O2 range. Although we
only tested one frequency in this study, our device has the ability to recreate longer or more
extreme hypoxic frequencies. While other studies have found results that may suggest that
intermittent hypoxia can increase proliferation or migration of fibroblasts, these studies often
cycle between 20% O2 and 1% O2.61 Even though we did not see these results in our intermittent
hypoxia condition, we believe that our results are more relevant to human physiology because
we chose to cycle between oxygen concentrations that are apparent in vivo.
To demonstrate the biological relevance of our device, we investigated the ability of constant
chronic and intermittent hypoxia to stimulate angiogenesis. In normoxia (5% O2), vessel growth
was relatively uniform into both adjacent tissue compartments. Although not statistically
different, small variances between the left and right compartments could be due to the slight
asymmetry in the design. Our device was able to recreate sprouting angiogenesis into a hypoxic
tissue microenvironment under both constant chronic and intermittent conditions. This
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observation is consistent with a normal biological response.25,61,62 The hypoxic conditions
generated less total vasculature than the normoxia case. This can be explained by the lower
mean oxygen tension within the vasculature chamber of the CH and IH cases (as low as 3.5%
and 2.5%, respectively, compared to 5%). The lower oxygen tension in the two hypoxic
conditions likely results in hypoxic stress to the vascular network and reduced overall sprouting.
The constant chronic hypoxia condition had more significant angiogenesis bias towards the low
oxygen chamber compared to the intermittent hypoxia condition as well as greater vessel area.
This is probably due to the range of oxygen concentrations we’ve chosen as well as frequency of
the cycle. Alternatively, as the constant chronic hypoxia case is a continuous exposure to
hypoxia, the stressed fibroblasts in the left chamber might have continually expressed proangiogenesis factors to encourage more vessel growth relative to the intermittent hypoxia
condition. As shown previously by our group, the frequency of the intermittent hypoxia cycles
can change how a vessel responds, which can be correlated to the amount of vascular endothelial
growth factor that is secreted by hypoxic fibroblasts.63

3.6 Conclusion
The results of this study show the effectiveness of microfluidic devices to control and manipulate
oxygen tension at high spatial and temporal resolution. The device design demonstrates the
ability to load different types of cells at different time points, which provides the opportunity to
model many different normal and pathological states. We chose 3D sprouting angiogenesis to
demonstrate the biological relevance of the device design, and we were able to replicate the welldescribed angiogenic response of hypoxic (constant chronic and intermittent) fibroblasts. The
simple and flexible design of the devices provides an opportunity to enhance understanding of
important disease processes present in cancer, ischemic heart disease, and wound healing.
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Chapter 4: Knockdown of HIF-1α Affects
MDA-MB-231 Survival under Spatial and
Temporal Oxygen Gradients
4.1 Abstract
The cost of guiding a clinical drug through discovery and development has been on the rise, and
it is now estimated that one drug can cost as much as $1.3 to $2.6 billion dollars. One method to
reduce costs is to create better platforms that more accurately replicates human disease
physiology in the pre-clinical phase to improve the efficiency and success in the clinical trial
phase. As cancer is the second leading cause of death in America, the development of new
therapies remain a priority. It been shown that tumor hypoxia, or low oxygen tension, contributes
to cancer drug resistance, yet most experiments mimicking cancer drug response are done at
atmospheric oxygen concentration (20% O2). This condition is a poor representation of hypoxic
tumor biology in vivo (< 5% O2). Furthermore, the leaky and tortuous nature of tumor
vasculature contributes to an oxygen tension that can fluctuate temporally between hypoxia and
normoxia (5% O2), a condition known as intermittent hypoxia. To replicate these dynamics of
the tumor microenvironment, we have designed a microfluidic device that can control the spatial
and temporal gradients of oxygen using an oxygen scavenger, sodium sulfite, to create an oxygen
sink. The scavenger is placed in microfluidic line next to a tissue chamber that contains MDAMB-231 breast cancer cells grown in a fibrin gel. Finite element modeling were used to predict
the oxygen gradients achieved in the microfluidic device. We knocked down the expression of
hypoxia inducible factor 1 alpha, the key transcriptional regulator of hypoxia and a common
therapeutic target of tumor hypoxia, to understand how the tumor cells would survive in an
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oxygen gradient. We found that both the oxygen concentration and the duration spent at hypoxia
are critical determinants of tumor cell migration and survival. This study demonstrates that both
spatial and temporal dynamics of oxygen tension in the tumor microenvironment could impact
drug efficacy.

4.2 Introduction
Hypoxia, or low oxygen tension, has become a hallmark of tumor progression as tumor cell
proliferation commonly exceeds diffusion of oxygen from the local vascular network creating an
imbalance of supply and demand. Furthermore, clinical studies showed advanced breast cancer
having a lower oxygen tension (10 mmHg) than normal breast tissue (65 mmHg).10
Subsequently, hypoxia has been associated with poor patient prognosis due to gene expression
changes that tumor cells can undergo during this process. Some processes associated with tumor
hypoxia are migration, tumor angiogenesis, metabolic reprogramming, cancer stem cell
maintenance, dormancy, and immune evasion, all which can contribute to treatment
resistance.64,65 In addition, the heterogeneity of vasculature in the tumor microenvironment can
lead to instances of intermittent hypoxia of repeated oxygen tension < 5% O2 cycling with
normoxia. Nevertheless, both chronic (sustained oxygen tension < 5% O2) and intermittent
hypoxia have been shown to contribute to tumor progression.
Tumor response to hypoxia is controlled largely by the transcription factor hypoxia-inducible
factor 1 (HIF-1).22,66 HIF-1 has two subunits (HIF-1α and HIF-1β), and under normal oxygen
conditions, HIF-1α is rapidly degraded by a family of prolyl hydroxylases. However, when as
oxygen tension decreases, the action of the prolyl hydroxylases is progressively compromised
leading to increased levels of HIF-1α in the cytoplasm. HIF-1α is then free to translocate to the
nucleus where it forms a heterodimer with HIF-1β and binds to the hypoxia responsive elements
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(HRE) in the promoter region of many genes. For example, increased levels of HIF-1α can lead
to enhanced expression of pro-angiogenic factors such as vascular endothelial growth factor
(VEGF) and VEGFR1, VEGFR2, plasminogen activator inhibitor-1 (PAI-1), angioprotein-2
(Ang-2), and inducible nitric oxide synthase (iNOS).10 While it has been established that hypoxia
increases expression of HIF-1α, our understanding of how temporal changes in oxygen tension
influence HIF-1α is incomplete. Although preliminary data has shown support that cyclic
hypoxia may increase the presence of HIF-1α, no direct link has been made to hypoxia cycle
duration or magnitude.67–70 All these studies of various cancer types under intermittent hypoxia
showed that an increase in HIF-1α expression lead to tumor progression in terms of increased
tumor angiogenesis, metastasis, or increased stem-like properties due to downstream
signaling.67–70
Because HIF-1α plays such an important role during hypoxic tumor progression, it is a potential
target for tumor treatment. However, this has been met with varying success, likely due to our
incomplete understanding.71–73 While most studies have examined the degree of hypoxia74–76, we
hypothesize that temporal variations of oxygen also impact tumor progression. To study this
hypothesis, we knocked down HIF-1α in breast cancer MDA-MB-231 cells and applied both
spatial and time varying oxygen concentrations. Our results show that both the spatial and
temporal gradients of oxygen affect tumor survival and migration of MDA-MB-231, and that this
response is HIF-1α-dependent.

4.3 Methods
4.3.1 Construction of Microfluidic Device
In this study, we used a three chambered microfluidic device (Error! Not a valid bookmark
self-reference.). The chambers were connected to each other via capillary burst valves
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measuring 30 μm wide. The fibrin chamber (central compartment) is the largest with a volume of
0.06 mm3, and the adjacent tumor chambers (adjacent) are slightly smaller with a volume of 0.02
mm3. Media lines connect to the central chamber to feed the adjacent tumor chambers, and
interstitial flow is driven by a hydrostatic pressure head. Finally, microfluidic channels 100 μm
wide run parallel to the tumor chambers and are used to deliver the oxygen scavenger to the
device.

12 3

1: MDA-MB-231 cells
2: Fibrin
3. MDA-MB-231 cells

Fig. 4. 1 Device Schematic. Our device is about the size of a US dime (left image). It consists of three tissue
chambers (larger brown chambers) and two media lines (smaller brown lines). The outer chambers are loaded with
MDA-MB-231 cells in gel, and the central chamber is loaded with plain fibrin. Sodium sulfite is convected through
the scavenger line (blue), while the opposite line (red) is left open to atmosphere.

After the device design was created in AutoCAD (San Rafael, CA), the design was printed and
fabricated using standard photolithography methods. Briefly, SU-8 3050 (MicroChem, Newton,
MA), a negative photoresist, was spun on to a silicon wafer to a height of 100 μm. Using the
printed design, ultraviolet light was used to crossline the pattern into the photoresist. Next, a
developer was used to leave the crosslinked pattern on the wafer. This mold was then silanized
and polydimethylsiloxane (PDMS; Dow Corning, Elizabethtown, KY) was poured over the mold
at a mixture of 10:1 (w/w) polymer to curing agent. The polymer was then cured at 65 °C for at
32

least two hours. The PDMS was then peeled off and the devices were cut individually. The inlets
and outlets were punched out of the device using blunt needles. To bond the device to a glass
slide, both pieces were cleaned and then plasma treated. Once the device was sealed to the glass,
it was placed in a 120 °C oven for a minimum of 15 minutes. Finally, to sterilize the device
before experimentation, it was placed under ultraviolet light for 1 hour.

4.3.2 Finite Element Modeling
To understand the oxygen gradients achieved in our microfluidic device, a 3D model of mass and
momentum transport was created in COMSOL Multiphysics 5.2a (Burlington, MA). First,
understand the delivery of oxygen through the media lines, flow was modeled by solving the
steady state solution of the incompressible Navier-Stokes equations using a no slip boundary
condition for the walls. The different properties of the device are the same as those used
previously (Table 1). The modeling of the 3D oxygen gradients is the same as previously
described in Chapter 3.3.2. Briefly, the transport of diluted species module was used to mimic
the transport of oxygen through the PDMS layer. Michaelis-Meten kinetics was used to model
consumption of oxygen via cellular metabolism and the consumption of oxygen through the
sodium sulfite reaction was based on previously reported findings in literature.52

4.3.3 MDA-MB-231 Cell Culture
Breast cancer cells, MDA-MB-231 cells, were purchased for this study from Cell Biolabs, Inc.
(San Diego, CA) and grown in Dulbecco’s Modified Eagle Medium (DMEM, ThermoFisher,
Waltham, MA) containing 10% fetal bovine serum (FBS, Sigma-Aldrich, St. Louis, MO), 1% Lglutamine (ThermoFisher), and 1% penicillin streptomycin (ThermoFisher). Cells were cultured
in a humidified incubator at 37 °C, 5% CO2, and 20% O2 before loaded into the microfluidic
device.
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4.3.4 HIF-1α Knockdown in MDA-MB-231
For the scramble and shRNA HIF-1α lentiviral particle transduction (Santa Cruz Biotechnology,
Dallas, TX), we first seeded MDA-MB-231 in a 24-well plate at a concentration of 4.5 x 104
cells in each well and allowed to grow overnight to about 50% confluency. A 250 μl media
solution containing 5 μg mL-1 polybrene (Santa Cruz Biotechnology) was added dropwise to
each well. Next, a 250 μl solution of media and lentiviral particles at a dilution of 1:50 (v/v)
particles to media or a multiplicity of infection (MOI) of about 1 was added to each well. The
cells were allowed to incubate with the lentiviral particles for 18 hours before the media was
changed. Stable clones expressing the scramble and shRNA lentiviral particles were selected via
3 μg mL-1 concentration of puromycin dihydrochloride (Santa Cruz). These cells were then
tested for HIF-1α gene expression by qRT-PCR and then frozen.
To perform qRT-PCR, RNA was extracted and purified using the RNeasy Plus Mini Kit (Qiagen,
Venlo, Netherlands) to a concentration of 100 ng μl-1. A reverse transcription kit (Applied
Biosystems) was then used to convert the RNA to cDNA. HIF-1α gene expression was then
measured using Taqman Gene Expression Assays (HIF-1α: Hs00154153_m1, 18S:
Hs99999901_s1) using the CFX96 Real-Time PCR Detection System (Bio-Rad, Hercules, CA).
Relative HIF-1α gene expression for control MDA-MB-231 (Control), scramble MDA-MB-231
(Scramble), and shRNA HIF-1α MDA-MB-231 (shHIF-1α) were compared using the ΔΔCt
method.

4.3.5 Microfluidic Device Experiment
The central chamber was first loaded with fibrin by resuspending 16 mg mL-1 fibrinogen (SigmaAldrich) in Dubecco’s Phosphate Buffered Saline (DPBS, ThermoFisher) and mixing it with a 50
U mL-1 thrombin solution. This initiates the polymerization process, at which time the mixture
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was quickly pipetted into the central chamber. The gel was then incubated for 30 minutes at 37
°C to ensure the polymerization process was complete. Next, the adjacent chambers were loaded
with MDA-MB-231 cells at a concentration of 5 x 106 cells mL-1. The cells were mixed with the
fibrinogen solution, and then this cell-fibrinogen solution was mixed with thrombin before
pipetting it in to the left and right chambers. After complete polymerization of the fibrin gel,
DMEM was flown through the media lines connected to the central chamber. The devices were
then placed in a humidified incubator at 37 °C, 5% CO2, and 5% O2 overnight. The next day, the
devices were imaged and the sodium sulfite was added to the left scavenger channel at varying
concentrations. This treatment was applied for the next 6 days before stopping the experiment
and performing a live/dead stain and imaging the devices.
In this study, we performed 4 different chronic hypoxia (CH) and 2 different intermittent
hypoxia (IH) studies. To achieve a range of different oxygen tensions, we varied the sodium
sulfite concentrations. In the chronic hypoxia condition, we used 1mM (1CH), 2mM (2CH),
3mM (3CH), and 5mM (5CH) concentrations of sodium sulfite. The solutions were placed in a
syringe and tygon tubing (Saint-Gobain, Valley Forge, PA) was used to connect the syringe to
the devices. For the duration of the experiment, the solutions were delivered continuously at a
rate of 12 μl min-1 to maintain constant consumption of oxygen during the entire length of the
experiment. Together, the concentration of sodium sulfite and the flow rate of the solution
produced a mass flow rate that created a variety of desired oxygen gradients to affect the survival
of shHIF-1α cells. The two intermittent hypoxia studies were intended to have the same temporal
oxygen concentration average of the 1CH and 3CH conditions and were termed 1IH and 3IH
respectively. Based on previous literature, we used a 1:1 ratio of time spent flowing scavenger to
time with no scavenger flow.68,70 To ensure that 1IH had the same temporal oxygen
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concentration average as 1CH, we used a concentration of 3mM sodium sulfite and flowed it for
a total of 12 hours, before stopping flow for 12 hours. These calculations were based on the
reaction kinetics of sodium sulfite. Similarly, in our 3IH condition, we used a sodium sulfite
concentration of 9mM, and flowed it for a 1 hour cycle before stopping flow for an hour.
Overall, we could test a variety of spatial and temporal oxygen gradients on Control, Scramble,
and shHIF-1α cells.

4.3.6 Tumor Growth and Migration Quantification
To quantify the degree of tumor progression in our study, we split up this parameter into two
factors: growth and migration. Images of the microfluidic device were taken before hypoxia
treatment and at the end of the experiment. Each image was cropped to only contain the left,
central, or right chamber, and the images were randomized and analyzed for tumor area using
ImageJ. Tumor growth was defined as normalized tumor area (NTA), and is defined by the area
in the left or right chamber on the final day of the experiment divided by the same chamber on
day 1. The migration parameter we used was calculated by dividing the tumor area in the central
chamber by the total tumor area in the left, central, and right chamber on the final day of the
experiment.

4.3.7 Statistical Analysis
All conditions were performed using at least 3-6 biological replicates, and the results are
represented as mean ± SD. A Mann-Whitney test was applied to compare tumor growth in the
left and right chambers or migration parameter among shHIF-1α cells, Control or Scramble.
Statistical significance was considered at the p < 0.05 level, and GraphPad Prism 6 was used for
data analysis.
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4.4 Results
4.4.1 Microfluidic Device and Oxygen Concentration Profiles
As we have shown previously, our microfluidic device can produce reliable pressure and velocity
gradients to ensure the growth of the tissue inside the device. We were successfully able to
observe tumor progression over the seven days of the experiment with the ability to quantify
tumor growth as well as tumor migration.
To understand the oxygen gradients we would achieve, we used extensive finite element
modeling to predict the oxygen tension within the device (Fig. 4. 2). Various sodium sulfite
concentrations were used in the models and demonstrate that by decreasing the concentration of
scavenger, there is an attenuation of the oxygen gradient. The 1CH condition has an oxygen
concentration rate of 4.93% to 5% O2. On the other hand, the 5CH condition has an oxygen
concentration rate of 4.89% to 5% O2.
O2(%)
A

C

B

5CH

3CH

D

2CH

1CH

Fig. 4. 2 Model of the oxygen distributions for various sodium sulfite concentrations. (A) 5CH, (B) 3CH, (C) 2CH, and
(D) 1CH conditions show that decreasing the concentration of sodium sulfite attenuates the oxygen gradient in the
device.
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4.4.2 Response of MDA-MB-231 to Varying Oxygen Gradients
The first experiment compared the growth of Control cells grown in 20% O2 to the more
physiologically relevant 5% O2. We observed significantly more growth in 5% O2 compared to
20% O2 (7.461 ± 4.64 NTA compared to 1.292 ± 0.86, respectively). In addition we observed
significantly more migration in 5% O2 compared to 20% O2 (0.404 ± 0.184 compared to 0.008 ±
0.004, respectively) (Fig. 4. 3A and B).

Fig. 4. 3 There is enhanced tumor progression at 5% O2 compared to 20% 02 for Control MDA-MB-231 cells. (A)
Images of representative devices in 20% (purple) vs. 5% O2 (green). (B) Quantification of normalized tumor area
(left) and migration (right). *, p < 0.05; ****, p < 0.0001. Scale bar: 200 μm.

Furthermore, when applying the oxygen gradient to the Control cells, there was no significant
difference between the side that experienced the oxygen gradient (left) and the normoxia side
(right). After flowing a 1mM sodium sulfite near the left tissue chamber, the left tissue chamber
had a NTA of 6.4 ± 2.8 compared to the right chamber of 4.4 ± 1.9. Increasing the oxygen
scavenger concentration to 2mM, the left and right chambers had a NTA of 5.8 ± 2.6 and 6.5 ±
1.4 respectively. The 3 mM case had a NTA of 4.8 ± 2.6 in the left and 3.7 ± 1.2 in the right
chamber. Lastly, increasing the sodium sulfite concentration to 5mM had a NTA of 4.6 ± 3.0 and
6.3 ± 3.3 in the left and right chambers respectively. In all these conditions, there was no
statistical significance between the left and right sides (Fig. 4. 4A).
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Fig. 4. 4 Varying spatial and temporal gradients do not affect Control cell survival. (A) Chronic hypoxia conditions
were defined by flowing varying concentrations of sodium sulfite from 1mM (1CH), 2mM (2CH), 3mM (3CH), and
5mM (5CH). Normalized tumor area (NTA) was compared from the left chamber (blue, hypoxic side) to the right
chamber (red, normoxic side). There was no statistical significance between the two sides (left graph). Images from
each condition is shown on the right. The image in the left column is before the treatment of oxygen scavenger and
the image in the right column is after the treatment. (B) Intermittent hypoxia conditions were defined to have the
same temporal oxygen concentration gradient of flowing 1mM or 3mM of scavenger constantly (termed 1IH and
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3IH respectively). Quantification of NTA (left graph) showed no statistical significance between the left (hypoxic)
and right (normoxic side). Representative images of the experimental conditions are shown with images on the right.
Scale bar: 200 μm.

In addition, there was also no significant difference between the NTA of Control cells in the two
sides of the device under the intermittent hypoxia conditions. The 1IH condition had a NTA of
5.5 ± 2.0 and 6.0 ± 3.6 in the left and right chambers respectively. In the 3IH conditions, there
was also no statistical significance in NTA between the left (4.2 ± 3.1) and right (4.3 ± 2.1)
chambers (Fig. 4. 4B).

4.4.3 Scramble and shHIF-1α Growth under Varying Oxygen Gradients
After transducing the MDA-MB-231 cells with shRNA for HIF-1α, we observed an approximate
60% knockdown of gene expression of HIF-1α in the shHIF-1α cells compared to Control (Fig.
4. 5). Knockdown of HIF-1α abrogated tumor cell growth at 5% oxygen such that there was no
longer any difference in growth compared to 20%. (NTA 1.8 ± 0.6 compared to 1.1 ± 0.3 for
20% and 5% O2, respectively) (Fig. 4. 6A and B). Similarly, there was no difference in migration
between 20% and 5% O2 (0.25 ± 0.16 and 0.09 ±0.11 respectively).

Fig. 4. 5 Relative Gene Expression of Scramble and shRNA HIF-1α cells. Data from the qRT-PCR showed that
knockdown cells had roughly a 60% reduced expression of HIF-1α.
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Fig. 4. 6 Knockdown of HIF-1α impacts tumor progression at normoxia (A) Images of devices in the 20% O 2 (top)
and 5% O2 (bottom) at the start (left column) and end (right column) of the experiment. (B) Quantification of NTA
(left) and migration (right) shows no statistical difference between devices grown at 20% O 2 (purple) or 5% O2
(green) with shHIF-1α cells.

Knockdown of HIF-1α significantly impacted the response to spatial and time varying oxygen
concentration. First, there was no significant difference in tumor growth between the left and
right side of the chambers for 0, 1mM, or 2mM sodium sulfite (Fig. 4. 7). 3mM sodium sulfite
did not impact the Scramble cells (NTA of 3.7 ± 3.7 (left) and 4.0 ± 2.3 (right)); however, the
tumor cells in the left side (lower oxygen) of the shHIF-1α demonstrated less growth (0.8 ± 0.2
compared to 2.3 ± 0.9 in the left and right chambers, respectively, p < 0.05) (Fig. 4. 7D). A
similar trend was observed at 5mM sodium sulfite (4.5 ± 1.3 and 5.1 ± 0.7 respectively for the
Scramble, but 0.8 ± 0.7 and 3.0 ± 2.4 for the shHIF-1α, respectively, p < 0.01) (Fig. 4. 7E).
Additionally, Fig. 4. 8 shows the percentage of tumor growth in the left and right chambers for
the shHIF-1α cells. This was calculated by dividing the tumor area in the left or right chamber by
the total tumor area in the final day of the experiment. The tumor growth of the shHIF-1α cells
becomes severely impacted in the 3CH and 5CH conditions.
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Fig. 4. 7 Various oxygen concentration gradients modulate the survival of MDA-MB-231 cells with a knockdown of
HIF-1α. (A-E) Quantification of NTA for Scramble and shHIF-1α in various chronic hypoxia conditions (top graph).
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Scramble (left) and shHIF-1α (right) images before (top) and after (bottom) treatment are shown below. (A)
Normoxia had no statistical difference between the left and right chambers for both the Scramble and shHIF-1α
cells. (B) 1CH and (C) 2CH also had no statistical difference between the left and right chambers. (D) At 3CH,
Scramble had no statistical difference between the two chambers, but shHIF-1α had statistically less growth in the
left (hypoxic) chamber compared to the right. (E) 5CH had no statistical difference between the left and right
chambers for the Scramble cells, but had statistically significant difference between the two for the shHIF-1α cells.
Left chambers are represented in blue and right chambers are represented in red for Scramble (cross) and shHIF-1α
(blank) cells. *, p < 0.05; **, p < .01. Scale bar = 200 μm.

Fig. 4. 8 Percent tumor growth of shHIF-1α. As the concentration of sodium sulfite increases, the
more it impacts the tumor cell growth in the left chamber. At 3CH and 5CH conditions, this
impact becomes significant.

The cycles of intermittent hypoxia were performed to produce an oxygen tension with a temporal
average similar to the 1mM or 3mM CH condition. These conditions are termed 1IH and 3IH,
respectively. For our conditions, we used a ratio of 1:1 for the duration of applying the scavenger
to stopping the flow of scavenger. For 1IH, we applied long 12 hour cycles and saw no
significant difference between the two sides of the Scramble case (NTA of 3.4 ± 2.5 and 4.1 ±
1.2, respectively, for the left and right side of the device). However, with this longer 12 hour
cycle duration, we saw a significant difference between the left and right sides of the device in
the shHIF-1α case (NTA of 0.4 ± 0.2 and 2.1 ± 0.9, respectively, p < 0.05) (Fig. 4. 9A). With the
3IH condition, we used shorter 1 hour cycles of alternating scavenger flow and no flow. In this
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case, we saw no significant difference in either the Scramble (NTA of 4.3 ± 0.9 and 4.3 ± 1.0 for
the left and right sides, respectively) or the shHIF-1α condition (NTA of 3.0 ± 2.6 (left) and 3.7
± 2.5 (right)) (Fig. 4. 9B).

Fig. 4. 9 Temporal variations in oxygen tension affect the survival of shHIF-1α cells. (A-B) NTA is shown in the
upper graph, while representative images are shown below. (A) In the 1IH case, there was no statistical significance
between the growth in the left or right chambers of the Scramble cells. There was statistical significance in growth
between the left and right chambers for the shHIF-1α cells. (B) The 3IH condition had no statistical difference
between the left and right chambers in the Scramble and shHIF-1α cells. Left chambers are represented in blue and
right chambers are represented in red for Scramble (cross) and shHIF-1α (blank) cells. *, p < 0.05. Scale bar = 200
μm.

4.4.4 Migration parameter during hypoxic conditions
In addition to tumor growth, we measured tumor migration into the central chamber (Fig. 4. 10).
The Control cells had relatively similar migration values over all the conditions (averaging 0.42
± 0.18). In contrast, shHIF-1α cells had more variable migration values. Starting with normoxia,
the shHIF-1α cells had a migration parameter of 0.14 ± 0.09. The 5CH condition had no
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migration and the 3IH condition had the most migration with a value of 0.136 ± 0.19. Overall,
the Control cells had significantly more migration than the shHIF-1α cells except for the 4IH
condition, which had a p-value of 0.06. Lastly, the Scramble cells had similar migration values to
the Control cells with an average value of 0.3 ± 0.19 over all the conditions. There was no
significant difference between the Control and Scramble migration values.
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Fig. 4. 10 Knockdown of HIF-1α impacts the migration of MDA-MB-231 cells. Quantification of migration for each
oxygen gradient condition for the Control (black), Scramble (crisscross), and shHIF-1α (white) cells. In all
conditions except for 3IH, the Control cells had statistically significant more migration than shHIF-1α (*, p < 0.05
and ***, p < .001).

4.5 Discussion
As organ-on-a-chip technologies have become more advanced, there is a growing interest to
replicate disease states.77 However, disease states can be difficult to recapitulate due to their
complexity relative to normal physiology. During tumor progression, the rapid growth of tumor
cells requires an expanding vessel network to provide nutrients and oxygen to the growing
mass.10 However, the resulting vessel network is often leaky and tortuous.78 This difference in
vasculature network can lead to abnormal temporal and spatial oxygen gradients, and those
tumor cells that can persist in hypoxic microenvironments have been shown to be resistant to
traditional cancer treatments. Our study presents the design, fabrication, and testing of a
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microfluidic device that can control oxygen gradients both spatially and temporally. We have
shown that this device can be used to investigate mechanisms of hypoxia, such as the role of
HIF-1α in modulating temporal dynamics of oxygen concentration.
Our initial observation that MDA-MB-231 breast cancer cells have more growth and migration
in 5% O2 than 20% O2 suggests that these cells have adapted to have a survival advantage at a
normoxic oxygen tension. Knocking down HIF-1α completely abrogates this growth advantage
suggesting that MDA-MB-231 cells have a higher level of HIF-1α at normoxic oxygen levels.
To begin to understand the mechanisms that contribute to an enhanced level of HIF-1α, we
applied varying spatial and temporal oxygen gradients to Control, Scramble and shHIF-1α cells.
Our results for chronic hypoxia (not temporal variation) show that an observable change in tumor
cell growth can be detected within a very small range of oxygen tensions. There was no
detectable change in growth at 2 mM sodium sulfite (mean oxygen tension in the scavenger side
tumor chamber of 4.93%), yet 3mM sodium sulfite (mean oxygen tension in the scavenger side
tumor chamber of 4.90%) produced a significant reduction in growth. In other words, HIF-1α
provides a threshold oxygen concentration for enhanced MDA-MB-231 cancer cell growth.
Using equal cycles of scavenger flow and no flow, we chose intermittent hypoxic conditions that
have the same temporal average of 1CH and 3CH conditions. We chose these conditions because
they were near the threshold of showing no bias (1CH) or significant bias (3CH) between the left
and right shHIF-1α tissue chambers. Interestingly, although 1CH showed no variance between
the two sides, 1IH showed a significant difference between the left and right chambers. Under
this condition, a long cycle (12 hours) of 3mM scavenger flow followed by no flow was
adequate to induce a similar response of a constant 3mM sodium sulfite. In contrast, even
though 3CH had significant variation in tumor growth between the left and right chambers in the
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shHIF-1α condition, by choosing a relatively short cycle of 1 hour of scavenger flow and no
flow, the 3IH condition showed no significant difference. This is interesting because although
the temporal average oxygen concentration is the same between the corresponding chronic and
intermittent hypoxia conditions, the outcomes from the shHIF-1α differ in these two cases. This
result provides some insight into the necessary duration of hypoxia at the level of 4.9% to impact
cell proliferation: the duration should be longer than 1 hour, and 12 hours is adequate.
Lastly, we quantified a migration parameter between the Control, Scramble, and shHIF-1α. We
found that there was statistically more tumor migration in the Control cells than shHIF-1α in
every condition except for 3IH, which had p-value of 0.06. This is consistent with previous
studies that show that HIF-1α stimulates tumor migration.79,80 While we didn’t see any trends in
tumor migration between the different hypoxic conditions, it would be of interest to use different
fluorescent MDA-MB-231 cells in the left and right chambers to identify if more cells were
migrating from the left (hypoxic) chamber or the right (normoxia) chamber.

4.6 Conclusions
The aim of this study was to demonstrate the need to more accurately recapitulate the tumor
microenvironment for effective drug testing. We chose to control oxygen tension both
temporally and spatially and then examined tumor cell proliferation and migration -- indices of
tumor progression. While an attractive target of tumor hypoxia is HIF-1α, we have demonstrated
that the spatial and temporal complexities of the oxygen environment can potentially undermine
this strategy. Because the microfluidic device design we used has the ability to measure tumor
growth and migration throughout the length of the experiment, we were able to quantify tumor
progression over the course of oxygen treatment. Overall, we believe this microfluidic design is
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flexible enough to recapitulate some of the intricacies of the tumor microenvironment to give us
the opportunity to study tumor behavior under varying oxygen tensions.
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Chapter 5: Conclusions and Future
Directions
Since the first discovery of the cause of a cancer in 1731, many advancements have been made to
understand this disease.81 However, with each new discovery, we uncover so much more that we
do not understand. This creates many problems while trying to discover and test new cancer
treatments. Therefore, it is critical for scientists to develop platforms that can best recreate the
tumor microenvironment for both research and drug innovation applications.

5.1 Tumor-on-a-chip Systems
Microengineered physiological systems have become a promising technology for drug testing as
well as studying tumor biology.82 Due to its inherent small size, this approach reduces reagent
requirements which facilitates high-throughput testing, which is critical for anticancer drug prescreening applications. In addition, because most microphysiological systems are developed
using a clear plastic, researchers have the opportunity to watch tumor progression in terms of
growth, invasion, and metastasis in real time.83 This provides a huge advantage over animal
models, which is the current gold standard. While animal models can sustain complex tumor
microenvironments, it is unclear how accurately it can model human tumorigenesis.84 Thus, there
is great interest in developing better tumor models.
The tumor microenvironment consists of a complex mixture of cellular and non-cellular
components. The surrounding environment can include blood vessels, carcinoma associated
fibroblasts (CAFs), immune cells, and the extracellular matrix. It has become increasingly
recognized that the key to developing cancer treatments is our ability to recapitulate these aspects
of the tumor microenvironment. Recent studies have shown that the interaction between tumor
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cells and microenvironment has profound effects on the tumor’s behavior and drug
resistance.85,86 Many advancements have been made towards including the heterogeneous
mixture of cell types in the tumor microenvironment. Qin’s research lab used the high spatial
control of microfluidic devices to study how CAFs promote tumor spheroid invasion.87 Jeon’s
research group has developed a method for studying the process of tumor angiogenesis and how
tumor cells interact with the blood vessel network, which has implications for understanding
tumor metastasis.88 Furthermore, Businaro’s research group has studied the interaction between
tumor cells and the immune system to observe that the tumor cells can direct the migration of the
immune cells.89 Together, these groups have demonstrated that microphysiological systems can
incorporate multiple cell types to study their interaction during tumor progression.
Another important aspect to replicate in the tumor microenvironment is the tumor cells
interaction with non-cellular components. Often, this consists of mimicking the extracellular
matrix that’s present in the tumor microenvironment. It has been known that the matrix stiffness
increases in the tumor microenvironment. These parameters are easily modulated in
microengineered physiological systems, and Weaver’s research group has shown that by
replicating the increased stiffness of the extracellular matrix of the tumor microenvironment, it
promotes a more malignant behavior by modulating integrins, which is critical for our
understanding of cancer cell migration.90 Other studies have looked at how chemical gradients
affect tumor behavior.59,91 However, an important aspect of tumor biology to replicate is tumor
hypoxia, which has been proven to be difficult to model.

5.2 Hypoxia Disease Modelling
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Several strategies have been used to mimic hypoxia for disease modelling. One strategy from
Gerecht’s lab has been to develop a hydrogel that consumes oxygen in situ.92 They have shown
that their hypoxic hydrogels can promote neovascularization from a host tissue during
subcutaneous wound healing.92 McGuigan’s lab discovered a method of turning two-dimensional
cell cultures in to three-dimensional models of tumors by rolling a scaffold-tumor strip into a
cylinder. A gradient of oxygen then forms from the outside of the cylinder towards the center as
it is diffusion limited. By unrolling the strip, the research team showed that they were able to
understand the spatial mapping of cell metabolism within a tumor sphere.93 Another method of
modelling tumor hypoxia comes from the Whitesides’ lab and was termed Cells-in-Gels-in-Paper
(CiGiP). This method employs the layering of stacks of paper containing cells encapsulated in a
gel with the lower layers receiving less oxygen and nutrients than the top layers. The research
team identified that after deconstruction of the different layers, the bottom (hypoxic) cells were
more resistant to irradiation treatment.94
A trend for studying hypoxia has been to use microfluidic devices. With inherently small
features, there are very short diffusion times to manipulate oxygen tension. As mentioned in
Chapter 2, there are several strategies that employ microfluidic devices to control oxygen
gradients. Most include using a dedicated line for an oxygen sink to draw oxygen away from the
tissue chamber. This can be nitrogen gas, a chemical reaction, or another cell type consuming
oxygen. Chapters 3 and 4 detail a method of using sodium sulfite as a scavenger to control the
spatial and temporal gradients of oxygen. For all of these designs, an important consideration for
choosing an oxygen scavenger is the reaction rate. Because we wanted to switch the flow of
scavenger on and off quickly, we chose a scavenger that can react with oxygen quickly.
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5.3 Future Directions
Over the past 5 years, there has been increasing interest in using microphysiological systems to
resolve some of the critical issues in drug development. The more we can advance these models
of the human body, the more applicable they become to studying human physiology and
pathology. In the future, as more accurate models of tumor hypoxia become available, we can
begin to study how tumor metabolism adapts to these pressures. The ability for cancer cells to
alter their metabolism is one of the reasons tumors can thrive during hypoxia, and these changes
are now considered one of the hallmark features of cancer.95 This understanding of tumor
metabolism during hypoxia can give researchers new therapeutic targets. Furthermore, by
creating an accurate microfluidic device of tumor hypoxia, we can use this platform as a high
throughput method of testing the effectiveness of drugs to target hypoxia cancer cells. As these
are understood to be the hardest cells to target, developing an accurate model for tumor hypoxia
can help resolve these issues. While many challenges remain for developing chronic and
intermittent hypoxia, there remains growing interest to address these challenges and present new
and exciting opportunities for improved anticancer therapies.

52

References
1.

Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA. Cancer J. Clin. 68, 7–
30 (2018).

2.

Heron, M. & Anderson, R. N. Changes in the Leading Cause of Death: Recent Patterns in
Heart Disease and Cancer Mortality. NCHS Data Brief 254, 1–8 (2016).

3.

Carter, A. J. & Nguyen, C. N. A comparison of cancer burden and research spending
reveals discrepancies in the distribution of research funding. BMC Public Health 12,
(2012).

4.

DiMasi, J. A., Grabowski, H. G. & Hansen, R. W. Innovation in the pharmaceutical
industry: New estimates of R&amp;D costs. J. Health Econ. 47, 20–33 (2016).

5.

Sertkaya, A., Wong, H.-H., Jessup, A. & Beleche, T. Key cost drivers of pharmaceutical
clinical trials in the United States. Clin. Trials 13, 117–126 (2016).

6.

Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182–6
(1971).

7.

Hanahan, D. & Weinberg, R. A. Review Hallmarks of Cancer : The Next Generation. Cell
144, 646–674 (2011).

8.

Breast Cancer Survival Rates. at <https://www.cancer.org/cancer/breastcancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html>

9.

Yang, Y., Sun, M., Wang, L. & Jiao, B. HIFs, angiogenesis, and cancer. J. Cell. Biochem.
114, 967–74 (2013).

10.

Vaupel, P., Mayer, A. & Höckel, M. Tumor hypoxia and malignant progression. Methods
Enzymol. 381, 335–54 (2004).

11.

Wang, G. L., Jiang, B. H., Rue, E. A. & Semenza, G. L. Hypoxia-inducible factor 1 is a
basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl.
Acad. Sci. 92, 5510–5514 (1995).

12.

Byrne, M. B., Leslie, M. T., Gaskins, H. R. & Kenis, P. J. A. Methods to study the tumor
microenvironment under controlled oxygen conditions. Trends Biotechnol. 32, 556–563
(2014).

13.

Xie, J. et al. Hypoxia regulates stemness of breast cancer MDA-MB-231 cells. Med.
Oncol. 33, 1–7 (2016).

14.

Wu, D. & Yotnda, P. Induction and testing of hypoxia in cell culture. J. Vis. Exp. (2011).
doi:10.3791/2899
53

15.

PIRET, J.-P., MOTTET, D., RAES, M. & MICHIELS, C. CoCl 2 , a Chemical Inducer of
Hypoxia-Inducible Factor-1, and Hypoxia Reduce Apoptotic Cell Death in Hepatoma Cell
Line HepG2. Ann. N. Y. Acad. Sci. 973, 443–447 (2002).

16.

Dewhirst, M. W., Braun, R. D. & Lanzen, J. L. Temporal changes in pO2 of R3230Ac
tumors in fischer-344 rats. Int. J. Radiat. Oncol. 42, 723–726 (1998).

17.

Gilkes, D. M., Semenza, G. L. & Wirtz, D. Hypoxia and the extracellular matrix: drivers
of tumour metastasis. Nat Rev Cancer 14, 430–439 (2014).

18.

Harris, A. L. Hypoxia — a key regulatory factor in tumour growth. Nat Rev Cancer 2, 38–
47 (2002).

19.

Baudino, T. A. et al. c-Myc is essential for vasculogenesis and angiogenesis during
development and tumor progression. Genes Dev. 16, 2530–43 (2002).

20.

Grimes, D. R., Kelly, C., Bloch, K. & Partridge, M. A method for estimating the oxygen
consumption rate in multicellular tumour spheroids. J. R. Soc. Interface 11, 20131124
(2014).

21.

Liao, D. & Johnson, R. S. Hypoxia: a key regulator of angiogenesis in cancer. Cancer
Metastasis Rev. 26, 281–90 (2007).

22.

Semenza, G. L. Hypoxia-inducible factors: mediators of cancer progression and targets for
cancer therapy. Trends Pharmacol. Sci. 33, 207–14 (2012).

23.

Carmeliet, P. Angiogenesis in health and disease. Nat. Med. 9, 653–60 (2003).

24.

Zhou, W. et al. Assessment of hypoxia inducible factor levels in cancer cell lines upon
hypoxic induction using a novel reporter construct. PLoS One 6, e27460 (2011).

25.

Krock, B. L., Skuli, N. & Simon, M. C. Hypoxia-Induced Angiogenesis: Good and Evil.
Genes Cancer 2, 1117–1133 (2011).

26.

Funamoto, K. et al. A novel microfluidic platform for high-resolution imaging of a threedimensional cell culture under a controlled hypoxic environment. Lab Chip 12, 4855
(2012).

27.

Brennan, M. D., Rexius-Hall, M. L., Elgass, L. J. & Eddington, D. T. Oxygen control with
microfluidics. Lab Chip 14, 4305–4318 (2014).

28.

Wang, L. et al. Construction of oxygen and chemical concentration gradients in a single
microfluidic device for studying tumor cell–drug interactions in a dynamic hypoxia
microenvironment. Lab Chip 13, 695–705 (2013).

29.

Ochs, C. J., Kasuya, J., Pavesi, A. & Kamm, R. D. Oxygen levels in thermoplastic
microfluidic devices during cell culture. Lab Chip 14, 459–462 (2013).

30.

Clark, L. C. & Lyons, C. ELECTRODE SYSTEMS FOR CONTINUOUS
MONITORING IN CARDIOVASCULAR SURGERY. Ann. N. Y. Acad. Sci. 102, 29–45
54

(2006).
31.

Esipova, T. V et al. Two new ‘protected’ oxyphors for biological oximetry: properties and
application in tumor imaging. Anal. Chem. 83, 8756–65 (2011).

32.

Griffith, C. K. et al. Diffusion Limits of an in Vitro Thick Prevascularized Tissue. Tissue
Eng. 11, 257–266 (2005).

33.

Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249
(2000).

34.

Goodall, C. M., Sanders, A. G. & Shubik, P. Studies of Vascular Patterns in Living
Tumors With a Transparent Chamber Inserted in Hamster Cheek Pouch2. JNCI J. Natl.
Cancer Inst. 35, 497–521 (1965).

35.

Semenza, G. L. Oxygen Sensing, Hypoxia-Inducible Factors, and Disease
Pathophysiology. Annu. Rev. Pathol. Mech. Dis. 9, 47–71 (2014).

36.

Rofstad, E. K., Galappathi, K., Mathiesen, B. & Ruud, E. B. M. Fluctuating and diffusionlimited hypoxia in hypoxia-induced metastasis. Clin. Cancer Res. 13, 1971–1978 (2007).

37.

Stavri, G. T., Zachary, I. C., Baskerville, P. A., Martin, J. F. & Erusalimsky, J. D. Basic
Fibroblast Growth Factor Upregulates the Expression of Vascular Endothelial Growth
Factor in Vascular Smooth Muscle Cells : Synergistic Interaction With Hypoxia.
Circulation 92, 11–14 (1995).

38.

Gurdon, J. B. & Bourillot, P.-Y. Morphogen gradient interpretation. Nature 413, 797–803
(2001).

39.

Helm, C.-L. E., Fleury, M. E., Zisch, A. H., Boschetti, F. & Swartz, M. A. Synergy
between interstitial flow and VEGF directs capillary morphogenesis in vitro through a
gradient amplification mechanism. Proc. Natl. Acad. Sci. 102, 15779–15784 (2005).

40.

Lo, J. F., Sinkala, E. & Eddington, D. T. Oxygen gradients for open well cellular cultures
via microfluidic substrates. Lab Chip 10, 2394 (2010).

41.

Germain, T., Ansari, M. & Pappas, D. Observation of reversible, rapid changes in drug
susceptibility of hypoxic tumor cells in a microfluidic device. Anal. Chim. Acta 936, 179–
184 (2016).

42.

Toffoli, S. et al. NDRG1 and CRK-I/II are regulators of endothelial cell migration under
intermittent hypoxia. Angiogenesis 12, 339–354 (2009).

43.

Tellier, C. et al. Cycling Hypoxia Induces a Specific Amplified Inflammatory Phenotype
in Endothelial Cells and Enhances Tumor-Promoting Inflammation In Vivo. Neoplasia 17,
66–78 (2015).

44.

Lo, J. F. et al. Islet Preconditioning via Multimodal Microfluidic Modulation of
Intermittent Hypoxia. Anal. Chem. 84, 1987–1993 (2012).
55

45.

Chen, Y.-A. et al. Generation of oxygen gradients in microfluidic devices for cell culture
using spatially confined chemical reactions. Lab Chip 11, 3626–33 (2011).

46.

Vaupel, P., Briest, S. & Hockel, M. Hypoxia in Breast Cancer: Pathogenesis,
Characterization and Biological/Therapeutic Implications. Wiener Medizinische
Wochenschrift 152, 334–342 (2002).

47.

Ehsan, S. M. & George, S. C. Nonsteady State Oxygen Transport in Engineered Tissue:
Implications for Design. Tissue Eng. Part A 19, 1433–1442 (2013).

48.

Buchwald, P. FEM-based oxygen consumption and cell viability models for avascular
pancreatic islets. Theor. Biol. Med. Model. 6, 5 (2009).

49.

Hsu, Y.-H. et al. Full range physiological mass transport control in 3D tissue cultures. Lab
Chip 13, 81–89 (2013).

50.

Moya, M. L., Hsu, Y.-H., Lee, A. P., Hughes, C. C. W. & George, S. C. In Vitro Perfused
Human Capillary Networks. Tissue Eng. Part C Methods 19, 730–737 (2013).

51.

Hsu, Y.-H., Moya, M. L., Hughes, C. C. W., George, S. C. & Lee, A. P. A microfluidic
platform for generating large-scale nearly identical human microphysiological
vascularized tissue arrays. Lab Chip 13, 2990 (2013).

52.

Barron, C. H. & O’Hern, H. a. Reaction kinetics of sodium sulfite oxidation by the rapidmixing method. Chem. Eng. Sci. 21, 397–404 (1966).

53.

Hui, P. K. & Palmer, H. J. Uncatalyzed oxidation of aqueous sodium sulfite and its ability
to simulate bacterial respiration. Biotechnol. Bioeng. 37, 392–396 (1991).

54.

Cox, M. E. & Dunn, B. Oxygen diffusion in poly(dimethyl siloxane) using fluorescence
quenching. I. Measurement technique and analysis. J. Polym. Sci. Part A Polym. Chem.
24, 621–636 (1986).

55.

Digman, M. a, Caiolfa, V. R., Zamai, M. & Gratton, E. The phasor approach to
fluorescence lifetime imaging analysis. Biophys. J. 94, L14-6 (2008).

56.

White, S. M. et al. Implanted Cell-Dense Prevascularized Tissues Develop Functional
Vasculature That Supports Reoxygenation After Thrombosis. Tissue Eng. Part A 20,
2316–2328 (2014).

57.

Moya, M., Tran, D. & George, S. C. An integrated in vitro model of perfused tumor and
cardiac tissue. Stem Cell Res. Ther. 4 Suppl 1, S15 (2013).

58.

Moya, M. L., Alonzo, L. F. & George, S. C. Microfluidic device to culture 3D in vitro
human capillary networks. Methods Mol. Biol. 1202, 21–7 (2014).

59.

Shirure, V. S., Lezia, A., Tao, A., Alonzo, L. F. & George, S. C. Low levels of
physiological interstitial flow eliminate morphogen gradients and guide angiogenesis.
Angiogenesis 20, 493–504 (2017).
56

60.

Alonzo, L. F., Moya, M. L., Shirure, V. S. & George, S. C. Microfluidic device to control
interstitial flow-mediated homotypic and heterotypic cellular communication. Lab Chip
(2015). doi:10.1039/c5lc00507h

61.

Gaustad, J. V., Simonsen, T. G., Roa, A. M. A. & Rofstad, E. K. Tumors exposed to acute
cyclic hypoxia show increased vessel density and delayed blood supply. Microvasc. Res.
85, 10–15 (2013).

62.

Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249–
257 (2000).

63.

Ehsan, S. M. & George, S. C. Vessel network formation in response to intermittent
hypoxia is frequency dependent. J. Biosci. Bioeng. 120, 347–350 (2015).

64.

Vaupel, P. Tumor Hypoxia: Causative Factors, Compensatory Mechanisms, and Cellular
Response. Oncologist 9, 4–9 (2004).

65.

Vaupel, P. & Mayer, A. Hypoxia in cancer: significance and impact on clinical outcome.
Cancer Metastasis Rev 26, 225–239 (2007).

66.

Majmundar, A. J., Wong, W. J. & Simon, M. C. Hypoxia-Inducible Factors and the
Response to Hypoxic Stress. Mol. Cell 40, 294–309 (2010).

67.

Peng, Y.-J. et al. Heterozygous HIF-1α deficiency impairs carotid body-mediated
systemic responses and reactive oxygen species generation in mice exposed to intermittent
hypoxia. J. Physiol. 577, 705–716 (2006).

68.

Rofstad, E. K., Gaustad, J.-V., Egeland, T. A. M., Mathiesen, B. & Galappathi, K. Tumors
exposed to acute cyclic hypoxic stress show enhanced angiogenesis, perfusion and
metastatic dissemination. Int. J. Cancer 127, 1535–1546 (2010).

69.

Verduzco, D. et al. Intermittent Hypoxia Selects for Genotypes and Phenotypes That
Increase Survival, Invasion, and Therapy Resistance. PLoS One 10, e0120958 (2015).

70.

Bhaskara, V. K., Mohanam, I., Rao, J. S. & Mohanam, S. Intermittent hypoxia regulates
stem-like characteristics and differentiation of neuroblastoma cells. PLoS One 7, 1–10
(2012).

71.

Burroughs, S. K. et al. Hypoxia inducible factor pathway inhibitors as anticancer
therapeutics. Future Med. Chem. 5, 553–572 (2013).

72.

Harrison, M. R. et al. Phase II study of 2-methoxyestradiol (2ME2) NanoCrystal
Dispersion (NCD) in patients with taxane-refractory, metastatic hormone-refractory
prostate cancer (HRPC). J. Clin. Oncol. 26, 5173–5173 (2008).

73.

Aeterna Zentaris Regains North American Rights to Akt Inhibitor from Keryx | GEN. at
<https://www.genengnews.com/gen-news-highlights/aeterna-zentaris-regains-northamerican-rights-to-akt-inhibitor-from-keryx/81246731/>

74.

Hudson, C. C. et al. Regulation of hypoxia-inducible factor 1alpha expression and
57

function by the mammalian target of rapamycin. Mol. Cell. Biol. 22, 7004–14 (2002).
75.

Mabjeesh, N. J. et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting
microtubules and dysregulating HIF. Cancer Cell 3, 363–375 (2003).

76.

Feldser, D., Agani, F. & Iyer, N. V. Reciprocal Positive Regulation of Hypoxia-inducible
Factor 1 α and Insulin-like Growth Factor 2 Growth Factor 2. Cancer Res. 59, 3915–3918
(1999).

77.

Sutherland, M. L., Fabre, K. M. & Tagle, D. a. The National Institutes of Health
Microphysiological Systems Program focuses on a critical challenge in the drug discovery
pipeline. Stem Cell Res. Ther. 4, I1 (2013).

78.

Matsumoto, S., Yasui, H., Mitchell, J. B. & Krishna, M. C. Imaging Cycling Tumor
Hypoxia. Cancer Res. 70, 10019–10023 (2010).

79.

Liu, L. et al. Hypoxia‑inducible factor 1 mediates intermittent hypoxia‑induced migration
of human breast cancer MDA‑MB‑231 cells. Oncol. Lett. 14, 7715–7722 (2017).

80.

Tátrai, E. et al. Cell type-dependent HIF1 α-mediated effects of hypoxia on proliferation,
migration and metastatic potential of human tumor cells. Oncotarget 8, 44498–44510
(2017).

81.

Kipling, M. D., Usherwood, R. & Varley, R. A monstrous growth: an historical note on
carcinoma of the scrotum. Br. J. Ind. Med. 27, 382–4 (1970).

82.

Low, L. A. & Tagle, D. A. Tissue chips – innovative tools for drug development and
disease modeling. Lab Chip 17, 3026–3036 (2017).

83.

Heylman, C., Sobrino, A., Shirure, V. S., Hughes, C. C. & George, S. C. A strategy for
integrating essential three-dimensional microphysiological systems of human organs for
realistic anticancer drug screening. Exp. Biol. Med. 239, 1240–1254 (2014).

84.

Klausner, R. D. Studying cancer in the mouse. Oncogene 18, 5249–5252 (1999).

85.

Bhadriraju, K. & Chen, C. S. Engineering cellular microenvironments to improve cellbased drug testing. Drug Discov. Today 7, 612–620 (2002).

86.

Birgersdotter, A., Sandberg, R. & Ernberg, I. Gene expression perturbation in vitro—A
growing case for three-dimensional (3D) culture systems. Semin. Cancer Biol. 15, 405–
412 (2005).

87.

Liu, T., Lin, B. & Qin, J. Carcinoma-associated fibroblasts promoted tumor spheroid
invasion on a microfluidic 3D co-culture device. Lab Chip 10, 1671 (2010).

88.

Kim, S., Lee, H., Chung, M. & Jeon, N. L. Engineering of functional, perfusable 3D
microvascular networks on a chip. Lab Chip 13, 1489 (2013).

89.

Agliari, E. et al. Cancer-driven dynamics of immune cells in a microfluidic environment.
Sci. Rep. 4, 6639 (2015).
58

90.

Paszek, M. J. et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 8,
241–254 (2005).

91.

Wang, S., Saadi, W., Lin, F., Minh-Canh Nguyen, C. & Li Jeon, N. Differential effects of
EGF gradient profiles on MDA-MB-231 breast cancer cell chemotaxis. Exp. Cell Res.
300, 180–189 (2004).

92.

Park, K. M. & Gerecht, S. Hypoxia-inducible hydrogels. Nat. Commun. 5, 4075 (2014).

93.

Rodenhizer, D. et al. A three-dimensional engineered tumour for spatial snapshot analysis
of cell metabolism and phenotype in hypoxic gradients. Nat. Mater. 15, (2015).

94.

Simon, K. A. et al. Metabolic Response of Lung Cancer Cells to Radiation in a PaperBased 3D Cell Culture System. Biomaterials (2016).
doi:10.1016/j.biomaterials.2016.03.002

95.

Fouad, Y. A. & Aanei, C. Revisiting the hallmarks of cancer. Am. J. Cancer Res. 7, 1016–
1036 (2017).

59

